ClinicalTrials.Veeva

Menu

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

A

ArsenalBio

Status and phase

Enrolling
Phase 1

Conditions

Ovarian Neoplasms
Abdominal Neoplasm
Carcinoma, Ovarian Epithelial
Neoplasms, Glandular and Epithelial
Genital Neoplasm, Female
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Recurrence
Ovarian Diseases

Treatments

Biological: AB-1015

Study type

Interventional

Funder types

Industry

Identifiers

NCT05617755
AB-1015-101

Details and patient eligibility

About

This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.

Full description

This study is intended for the patients who have been diagnosed with Epithelial Ovarian Cancer that either came back or did not improve after platinum treatments (platinum resistant). The purpose of this study is to test the safety of using a new treatment called Integrated Circuit T (ICT) cells (AB-1015 cells) in patients with ovarian cancer. This treatment has not been approved by the Food and Drug Administration.

The goal of this study is to calculate the maximum tolerated dose of the AB-1015 cells. T cells are part of the immune system that protect the body from infection and may help fight cancer. The T cells given in this study will come from the patient and will have a genetic circuit/logic gate put in them that makes them able to recognize alkaline phosphatase, germ line/placental (ALPG/P) and mesothelin (MSLN), 2 proteins on the surface of tumor cells. These logic-gated T cells may help the body's immune system identify and kill cancer cells while sparing normal healthy tissues from toxicity.

The AB-1015 cells are given intravenously, after completing 3 rounds of conditioning chemotherapy administered over 3 consecutive days. Conditioning chemotherapy prepares the body to receive the AB-1015 cells. If they continue to meet the eligibility criteria, AB-1015 cells will be given to them 2 days after the last conditioning chemotherapy round. A single infusion of the AB-1015 cells will be given to the subject intravenously.

After completion of study treatment, patients are followed with serial measurements of safety, tolerability and response.

This is a research study to obtain new information that may help people in the future.

Enrollment

60 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Recurrent, advanced, platinum resistant ovarian, fallopian tube, and primary peritoneal cancer and must have a histological diagnosis of a high-grade serous histology.
  • a) Platinum resistant disease is defined as progression of disease within six months of platinum regimen.
  • Doubling of cancer antigen 125 (CA-125) level on 2 successive measurements may be considered as meeting the definition of disease progression
  • b) Have received at least 2 lines of prior therapy including a platinum-based regimen if eligible and a poly-ADP ribose polymerase (PARP) inhibitor if BRCA1/2 mutated. No more than 3 lines of prior therapy for the treatment of platinum resistant disease is permitted.
  • Adequate organ function as per protocol definitions.
  • Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1.
  • Evaluable disease (dose escalation cohorts) or measurable disease (backfill cohorts) at time of enrollment as per protocol definitions.
  • Negative pregnancy test for women of childbearing potential. Women of non-childbearing potential are those who have been surgically sterilized, have medically confirmed ovarian failure, or have not had menses within the past 12 months.

Exclusion criteria

  • Cytotoxic chemotherapy within 14 days of time of cell collection.
  • Cytotoxic chemotherapy within 14 days of starting of conditioning chemotherapy.
  • New York Heart Association functional class II-IV cardiovascular disability
  • Clinically significant pericardial effusion
  • Pleural or peritoneal effusion that requires drainage for symptom management within 28 days of screening.
  • Active autoimmune disease requiring immunosuppressive therapy or uncontrolled with treatment.
  • Untreated brain metastasis.
  • Subjects unwilling to participate in an extended safety monitoring period.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

60 participants in 1 patient group

AB-1015
Experimental group
Description:
Patients receive fludarabine and cyclophosphamide intravenously on days -5 to -3. Patients receive a single dose of AB-1015 intravenously on day 0.
Treatment:
Biological: AB-1015

Trial contacts and locations

10

Loading...

Central trial contact

Arsenal Biosciences

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems